DBV Technologies SA ADR DBVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DBVT is a good fit for your portfolio.
News
-
DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
-
DBV Technologies Announces Plan to Implement ADS Ratio Change
-
DBV Technologies to Participate in Upcoming EAACI 2024 Congress
-
DBV Technologies Announces Plan to Implement ADS Ratio Change
-
DBV Technologies Announces Results of its 2024 Combined General Meeting
-
DBV Technologies to Participate in Upcoming Investor Conferences
-
DBV Technologies Reports First Quarter 2024 Financial Results and Business Update
Trading Information
- Previous Close Price
- $1.05
- Day Range
- $1.01–1.05
- 52-Week Range
- $0.90–4.50
- Bid/Ask
- $1.01 / $1.05
- Market Cap
- $101.05 Mil
- Volume/Avg
- 186,744 / 70,034
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 105
- Website
- http://www.dbvtechnologies.com
Comparables
Valuation
|
Metric
|
DBVT
|
MLTX
|
AVTE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.90 | 4.85 | 6.71 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DBVT
|
MLTX
|
AVTE
|
|---|---|---|---|
Quick Ratio | 4.45 | 61.56 | 6.94 |
Current Ratio | 4.51 | 62.13 | 7.04 |
Interest Coverage | — | — | — |
Quick Ratio
DBVT
MLTX
AVTE
Profitability
|
Metric
|
DBVT
|
MLTX
|
AVTE
|
|---|---|---|---|
Return on Assets (Normalized) | −38.57% | −9.28% | −54.44% |
Return on Equity (Normalized) | −50.56% | −10.06% | −61.39% |
Return on Invested Capital (Normalized) | −51.29% | −9.46% | −65.19% |
Return on Assets
DBVT
MLTX
AVTE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mfgvxfc | Lrslp | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zjdnjlyz | Rbygmn | $110.4 Bil | |||
| Moderna Inc
MRNA
| Jyrvclwr | Sqntt | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Bmtjjlzr | Qmbt | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Nxvfnrpjj | Dpfl | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dpqhzzv | Pkflmrn | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Czgsjwlv | Qlfmgr | $15.3 Bil | |||
| Incyte Corp
INCY
| Ygjcgmnw | Hzttdhl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ybpghwtrf | Wfkcwwq | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Chntkfdh | Ckfq | $12.2 Bil |